找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Immunotherapy for Gastrointestinal Malignancies; Ramakrishna Vadde,Ganji Purnachandra Nagaraju Book 2020 The Editor(s) (if applicable) and

[復(fù)制鏈接]
樓主: 驅(qū)逐
31#
發(fā)表于 2025-3-27 00:01:48 | 只看該作者
32#
發(fā)表于 2025-3-27 04:23:02 | 只看該作者
Tumor Heterogeneity: Challenges and Perspectives for Gastrointestinal Cancer Therapy,son for the low treatment response rate in cancer patients. Thus, there is always a quest to understand the tumor heterogeneity in any cancer type. In this chapter, the authors attempted to understand the types and drivers for tumor heterogeneity, especially in gastrointestinal cancers, and discusse
33#
發(fā)表于 2025-3-27 05:35:34 | 只看該作者
Immunocomposition of Gastrointestinal Tract of Gut,rwhelming load of antigens in the form of dietary antigens on a daily basis. The GI tract has played dual role in the body, in that it performs uptake of nutrients and digestion while also performing out the complex and principal task of maintaining immune homeostasis, i.e., maintaining the balance
34#
發(fā)表于 2025-3-27 11:43:56 | 只看該作者
35#
發(fā)表于 2025-3-27 16:05:21 | 只看該作者
36#
發(fā)表于 2025-3-27 19:34:49 | 只看該作者
Immune Cell Therapy Against Gastrointestinal Tract Cancers, the healthcare sector across the globe. Recently advancements in high throughput techniques provide us with a unique opportunity to detect biomarkers and treat various diseases, including GI cancer, more comprehensively. However, most of these approaches are ineffective for treating patients with a
37#
發(fā)表于 2025-3-28 01:23:56 | 只看該作者
Immune Checkpoint Inhibitors in Gastrointestinal Malignancies,se of cancer related deaths. GI cancers are treated by surgery, radiotherapy, and chemotherapy. The overall survival rate (5 years of survival) after the surgery is very poor in patients with GI cancers. To increase the survival rate adjuvant therapies like chemotherapy and radiotherapy were perform
38#
發(fā)表于 2025-3-28 05:57:20 | 只看該作者
39#
發(fā)表于 2025-3-28 06:33:32 | 只看該作者
40#
發(fā)表于 2025-3-28 11:12:25 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-25 23:59
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
山东省| 元氏县| 安吉县| 庆阳市| 巴楚县| 青铜峡市| 哈密市| 淮阳县| 古田县| 胶南市| 交城县| 略阳县| 西乡县| 岳西县| 香河县| 象州县| 万盛区| 金溪县| 泾川县| 金门县| 阿合奇县| 彝良县| 夏津县| 会宁县| 玉山县| 娱乐| 荥阳市| 旬阳县| 赤峰市| 洛阳市| 垫江县| 巴楚县| 牟定县| 柏乡县| 清丰县| 繁昌县| 大冶市| 金门县| 克山县| 南宁市| 沂南县|